Saturday 17 October 2026
Export REVB’s income statement to Excel — free account
Revelation Biosciences, Inc.
REVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.9% and free cash flow fell 35.3%, each against the same quarter a year earlier.
0.49
0.27
−35.53%
Follow REVB
Revelation Biosciences, Inc. (REVB) P/E ratio
Revelation Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.7× (January 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.7×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BCAB BioAtla, Inc. compare | n/m |
| REVB Revelation Biosciences, Inc. | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| ARAV ARAVIVE, INC compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | 0.0× |
| DCOY Decoy Therapeutics Inc compare | 0.0× |
| GRI GRI Bio, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)